头孢布烯治疗墨西哥成人无并发症尿路感染的经济评价

A. Reyes-López , V. Blandón-Vijil
{"title":"头孢布烯治疗墨西哥成人无并发症尿路感染的经济评价","authors":"A. Reyes-López ,&nbsp;V. Blandón-Vijil","doi":"10.1016/j.uromx.2015.11.002","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Urinary tract infections are a leading cause of medical consultations in Mexico and the growth of antimicrobial resistance results in increased morbidity and rising costs.</p></div><div><h3>Aim</h3><p>To make an economic evaluation of ceftibuten as treatment for uncomplicated urinary tract infections in adults, from the perspective of the Mexican private health system.</p></div><div><h3>Methods</h3><p>A cohort-based decision-making model was developed to compare ceftibuten with TMP-SMX, ciprofloxacin, and cefalexin. Effectiveness was measured using local susceptibility rates of <em>Escherichia coli</em>. Costs were obtained from official market value data and converted to 2014 USD values. Incremental analysis was employed to determine if ceftibuten was a worthwhile investment on the part of the private health system in Mexico.</p></div><div><h3>Results</h3><p>The total expected cost per patient for ciprofloxacin was $116 USD and the corresponding costs for TMP/SMX and cefalexin were $92.40 USD and $74.80 USD, respectively. Ceftibuten had a lower expected cost ($34.50 USD) and a higher percentage of therapeutic success (99.4%), compared with ciprofloxacin 21%, cefalexin 41%, and TMP/SMX 31.7%.</p></div><div><h3>Conclusions</h3><p>Even though ceftibuten has a higher market price than other antimicrobials in Mexico, it can represent possible savings by avoiding the costs associated with undesirable results due to antimicrobial resistance to <em>E. coli</em>.</p></div>","PeriodicalId":34909,"journal":{"name":"Revista mexicana de urologia","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.uromx.2015.11.002","citationCount":"1","resultStr":"{\"title\":\"Economic evaluation of ceftibuten in the treatment of uncomplicated urinary tract infections in adult Mexican patients\",\"authors\":\"A. Reyes-López ,&nbsp;V. Blandón-Vijil\",\"doi\":\"10.1016/j.uromx.2015.11.002\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><p>Urinary tract infections are a leading cause of medical consultations in Mexico and the growth of antimicrobial resistance results in increased morbidity and rising costs.</p></div><div><h3>Aim</h3><p>To make an economic evaluation of ceftibuten as treatment for uncomplicated urinary tract infections in adults, from the perspective of the Mexican private health system.</p></div><div><h3>Methods</h3><p>A cohort-based decision-making model was developed to compare ceftibuten with TMP-SMX, ciprofloxacin, and cefalexin. Effectiveness was measured using local susceptibility rates of <em>Escherichia coli</em>. Costs were obtained from official market value data and converted to 2014 USD values. Incremental analysis was employed to determine if ceftibuten was a worthwhile investment on the part of the private health system in Mexico.</p></div><div><h3>Results</h3><p>The total expected cost per patient for ciprofloxacin was $116 USD and the corresponding costs for TMP/SMX and cefalexin were $92.40 USD and $74.80 USD, respectively. Ceftibuten had a lower expected cost ($34.50 USD) and a higher percentage of therapeutic success (99.4%), compared with ciprofloxacin 21%, cefalexin 41%, and TMP/SMX 31.7%.</p></div><div><h3>Conclusions</h3><p>Even though ceftibuten has a higher market price than other antimicrobials in Mexico, it can represent possible savings by avoiding the costs associated with undesirable results due to antimicrobial resistance to <em>E. coli</em>.</p></div>\",\"PeriodicalId\":34909,\"journal\":{\"name\":\"Revista mexicana de urologia\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2016-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/j.uromx.2015.11.002\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Revista mexicana de urologia\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2007408515001421\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista mexicana de urologia","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2007408515001421","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 1

摘要

尿路感染是墨西哥医疗咨询的主要原因,抗菌素耐药性的增长导致发病率上升和成本上升。目的从墨西哥私立卫生系统的角度对头孢布烯治疗成人无并发症尿路感染进行经济评价。方法建立基于队列的决策模型,将头孢布烯与TMP-SMX、环丙沙星、头孢氨苄进行比较。使用当地大肠杆菌的敏感性来衡量有效性。成本来自官方市场价值数据,并转换为2014年美元价值。采用增量分析来确定头孢布酮对墨西哥私人卫生系统的部分投资是否值得。结果环丙沙星的预期总成本为116美元/例,TMP/SMX和头孢氨苄的预期总成本分别为92.40美元和74.80美元/例。与环丙沙星21%、头孢氨苄41%和TMP/SMX 31.7%相比,头孢布烯的预期成本更低(34.50美元),治疗成功率更高(99.4%)。结论尽管头孢布烯在墨西哥的市场价格高于其他抗菌素,但它可以避免因大肠杆菌耐药而导致的不良后果,从而节省成本。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Economic evaluation of ceftibuten in the treatment of uncomplicated urinary tract infections in adult Mexican patients

Background

Urinary tract infections are a leading cause of medical consultations in Mexico and the growth of antimicrobial resistance results in increased morbidity and rising costs.

Aim

To make an economic evaluation of ceftibuten as treatment for uncomplicated urinary tract infections in adults, from the perspective of the Mexican private health system.

Methods

A cohort-based decision-making model was developed to compare ceftibuten with TMP-SMX, ciprofloxacin, and cefalexin. Effectiveness was measured using local susceptibility rates of Escherichia coli. Costs were obtained from official market value data and converted to 2014 USD values. Incremental analysis was employed to determine if ceftibuten was a worthwhile investment on the part of the private health system in Mexico.

Results

The total expected cost per patient for ciprofloxacin was $116 USD and the corresponding costs for TMP/SMX and cefalexin were $92.40 USD and $74.80 USD, respectively. Ceftibuten had a lower expected cost ($34.50 USD) and a higher percentage of therapeutic success (99.4%), compared with ciprofloxacin 21%, cefalexin 41%, and TMP/SMX 31.7%.

Conclusions

Even though ceftibuten has a higher market price than other antimicrobials in Mexico, it can represent possible savings by avoiding the costs associated with undesirable results due to antimicrobial resistance to E. coli.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Revista mexicana de urologia
Revista mexicana de urologia Medicine-Urology
CiteScore
0.20
自引率
0.00%
发文量
49
期刊介绍: Revista Mexicana de Urología (RMU) [Mexican Journal of Urology] (ISSN: 0185-4542 / ISSN electronic: 2007-4085) is bimonthly publication that disseminates research by academicians and professionals of the international medical community interested in urological subjects, in the format of original articles, clinical cases, review articles brief communications and letters to the editor. Owing to its nature, it is publication with international scope that disseminates contributions in Spanish and English that are rigorously reviewed by peers under the double blind modality. Neither journalistic documents nor those that lack rigorous medical or scientific support are suitable for publication.
期刊最新文献
Fe de errores de «Resultados obtenidos con nefrolitotomía percutánea y su correlación con las escalas de Guy y S.T.O.N.E. en un hospital de la Ciudad de México» [Rev Mex Urol. 2016;76:331] Blindness due to a systemic fungal infection in a patient with a ureteral catheter Permixon® en el tratamiento de los síntomas del tracto urinario inferior por hiperplasia benigna de próstata: Nuevas aportaciones Resultados de la nefrectomía laparoscópica en pacientes obesos y no obesos Alfa-1 bloqueantes y resultados urodinámicos en varones con síntomas del tracto urinario inferior relacionados con obstrucción benigna de próstata: ¿fin de la controversia?
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1